esure Group plc (LON:ESUR) Stock “Add” Rating Reconfirmed at Peel Hunt; The TP Given is GBX 295.00; Edwards Lifesciences (EW) Covered By 22 Bullish Analysts Last Week

They currently have a GBX 295.00 price target on esure Group plc (LON:ESUR). Peel Hunt’s target would suggest a potential upside of 29.33% from the company’s last stock price. This was disclosed to clients in analysts note on 7 March.

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp had 106 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Priority List” rating on Monday, October 19 by Wells Fargo. BMO Capital Markets maintained Edwards Lifesciences Corporation (NYSE:EW) on Thursday, December 7 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, April 26 report. The firm has “Market Perform” rating given on Tuesday, April 5 by Northland Capital. Canaccord Genuity maintained the shares of EW in report on Thursday, July 27 with “Buy” rating. As per Thursday, February 15, the company rating was maintained by Canaccord Genuity. The stock has “Outperform” rating by Cowen & Co on Wednesday, April 27. As per Wednesday, October 25, the company rating was maintained by Barclays Capital. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Sell” rating given on Thursday, November 12 by Citigroup. BMO Capital Markets maintained the stock with “Buy” rating in Wednesday, January 17 report. See Edwards Lifesciences Corporation (NYSE:EW) latest ratings:

15/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $174.0 Maintain
02/02/2018 Broker: Guggenheim Rating: Buy New Target: $162.0 Maintain
01/02/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $155.0 Maintain
02/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $135 New Target: $140 Maintain
02/02/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $135 New Target: $155 Maintain
02/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $140.0 Maintain
01/02/2018 Broker: Jefferies Rating: Buy New Target: $150.0 Maintain
02/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $130 New Target: $138 Maintain
01/02/2018 Broker: BMO Capital Markets Rating: Buy New Target: $150.0 Maintain
01/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $174.0 Maintain

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $28.95 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 51.06 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.

The stock increased 1.18% or $1.61 during the last trading session, reaching $137.85. About 1.30 million shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since March 7, 2017 and is uptrending. It has underperformed by 1.29% the S&P500.

The stock increased 1.16% or GBX 2.6 during the last trading session, reaching GBX 227. About 404,410 shares traded. esure Group plc (LON:ESUR) has 0.00% since March 7, 2017 and is . It has underperformed by 16.70% the S&P500.